RBM15 and metabolic dysfunction-associated steatotic liver disease: Previous study indicated that excessive m6A modification led to enhanced ACLY and SCD1 expression in the nonalcoholic fatty liver disease (NAFLD) model.[40] Here, we demonstrate that RBM15, a m6A methylation modification “writer”, is bound to ACLY.